SAN DIEGO--(BUSINESS WIRE)--858 Therapeutics today announced an upcoming poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, California. The presentation will describe the preclinical characterization of ETX-19477, including potent antitumor activity in multiple animal models..

圣地亚哥--（商业新闻短讯）--858 Therapeutics今天宣布，将于4月5日至10日在加利福尼亚州圣地亚哥举行的2024年美国癌症研究协会（AACR）年会上发布海报。该演讲将描述ETX-19477的临床前表征，包括在多种动物模型中的有效抗肿瘤活性。。

Presentation Details for AACR 2024

AACR 2024演示详细信息

Abstract Number: 2083

摘要编号：2083

Title: Discovery of ETX-19477, a novel and selective PARG inhibitor with high potency against tumors with underlying replication stress

标题：ETX-19477的发现，ETX-19477是一种新型的选择性PARG抑制剂，对具有潜在复制应激的肿瘤具有高效力

Session Title: Novel Targets and Pathways

会议标题：新目标和途径

Session Date and Time: April 8, 2024, 9:00 AM – 12:30 PM (PDT)

会议日期和时间：2024年4月8日上午9:00–下午12:30（PDT）

About ETX-19477

关于ETX-19477

The company’s lead asset, ETX-19477, is a novel and potent small molecule inhibitor of PARG, a glycohydrolase that plays a pivotal role in the regulation of DNA repair mechanisms and cooperates with PARP to carry out the single-strand break repair cycle. Pharmacological inhibition of PARG results in hyperPARylation, which leads to the death of cancer cells undergoing replication stress.

该公司的主要资产ETX-19477是一种新型有效的PARG小分子抑制剂，PARG是一种糖水解酶，在调节DNA修复机制中起关键作用，并与PARP合作进行单链断裂修复循环。PARG的药理学抑制导致过度PARylation，这导致经历复制应激的癌细胞死亡。

In multiple animal models, ETX-19477 shows potent tumor growth inhibition, and its efficacy is associated with specific biomarker-defined tumors. A Phase I clinical trial is expected to start in the first half of 2024 in patients with advanced solid tumors at multiple sites in the U.S..

在多种动物模型中，ETX-19477显示出有效的肿瘤生长抑制作用，其功效与特定的生物标志物定义的肿瘤有关。预计将于2024年上半年在美国多个部位对晚期实体瘤患者进行I期临床试验。。

About 858 Therapeutics

约858种疗法

858 Therapeutics is a biotechnology and drug discovery company developing a portfolio of small molecule therapeutics directed against novel oncology targets. Its lead programs focus on important nodes in cancer biology, including DNA damage repair, innate immunity, and RNA epigenetics, and expand upon insights from over 20 years of work by the founders at predecessor companies.

858 Therapeutics是一家生物技术和药物发现公司，开发针对新型肿瘤学靶标的小分子疗法组合。其主要项目侧重于癌症生物学中的重要节点，包括DNA损伤修复，先天免疫和RNA表观遗传学，并扩展了前任公司创始人20多年工作的见解。

858 Therapeutics is funded by leading biotechnology investors, including Versant Ventures, NEA, Cormorant Asset Management, and Logos Capital. 858 is headquartered in the biotech hub of San Diego, CA. For more information, please visit www.8five8tx.com..

858 Therapeutics由领先的生物技术投资者资助，包括Versant Ventures，NEA，Cormorant Asset Management和Logos Capital。858总部位于加利福尼亚州圣地亚哥的生物技术中心。有关更多信息，请访问www.8five8tx.com。。